Latest news

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

FDA grants Breakthrough Therapy Designation for Debiopharm’s novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

Challenge pour la Qualité de vie du patient 2020 : l’appel à projets est ouvert

Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR…

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

Grand gagnant du Challenge 2019 pour la qualité de vie du patient, le projet Rise-Up de chaise élévatrice qui aide…

Après-demain Holding SA acquiert une participation dans le réseau de crèches Little Green House (Suisse)

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…